Company profile
CG Oncology Inc.
NASDAQ: CGON · Healthcare · Biotechnology
#726 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
47DFH 57DQ 29GM —SS 56
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$5.1M
Rev growth YoY (TTM)
+666.0%
Net income (FY)
-$161.0M
Employees
142
as of 2026-08-06
Market cap
$6.4B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.0M$4.0M2025
Net income-$161.0M-$161.0M2025
Operating income-$190.8M-$190.8M2025
Total assets$791.6M$791.6M2025
Liabilities$39.0M$39.0M2025
Equity$752.6M$752.6M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License And Collaboration Revenue100%
By geography
Not disclosed.
The read
What is CG Oncology Inc.’s revenue?
CG Oncology Inc. booked $4.0M in FY2025 revenue, growing 255% year over year — faster than 90% of Healthcare companies we track, at a -3985.0% net margin.
Peers · Healthcare
Comprehensive Healthcare Systems, Inc.42DInsight Molecular Diagnostics Inc.37DHemagen Diagnostics, Inc.——CervoMed Inc.42DTenon Medical, Inc.35DNovaBridge Biosciences36DNeighbors
Orange →Key facts
CEOArthur Kuan
SectorHealthcare
IndustryBiotechnology
HeadquartersIrvine, CA
ExchangeNASDAQ: CGON
Employees142
IPO date2024-01-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.